We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01221792
Recruitment Status : Unknown
Verified June 2011 by Columbia Northwest Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : October 15, 2010
Last Update Posted : June 8, 2011
Information provided by:
Columbia Northwest Pharmaceuticals

Brief Summary:
The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.

Condition or disease Intervention/treatment Phase
Post-Traumatic Stress Disorder Drug: Carvedilol Drug: Placebo Phase 2

Detailed Description:
This initial proof of concept trial design is intended to explore multiple variables. Fist, it is intended to determine if carvedilol has any statistically significant effect over placebo on the various overall symptoms, symptom clusters, or individual symptoms of post traumatic stress disorder. Next, the flexible dosing trial design is aimed to detect the therapeutic dose, or dosing range for carvedilol when used in the treatment of PTSD

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Carvedilol Versus Placebo in the Treatment of Post Traumatic Stress Disorder
Study Start Date : October 2010
Estimated Primary Completion Date : June 2011
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: carvedilol
Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
Drug: Carvedilol

Oral, twice daily dosing using 3.125 mg tablets.

1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day).

Other Name: Coreg(R)
Placebo Comparator: Sugar Pill
Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
Drug: Placebo
Non active comparator

Primary Outcome Measures :
  1. Davidson Trauma Scale (DTS) [ Time Frame: 5 weeks ]

    The DTS is a 17-item self report measure to assess the 17 DMS-IV symptoms of PTSD. Respondants are asked to identify the trauma that is most disturbing to them and to rate, in the past week, how much trouble they hav had with each symptom. The DTS can be used to make a preliminatry determination about whether the symptoms meet DSM criteria for PTSD, or scores can be calculated for each of the 3 PTSD symptom clusters.

    The DTS will be assessed at each study visit (visit 1, 2, 3, 4, 5, 6 and 7). The primary efficacy outcome will be change from baseline (visit 2) to week 5 (visit 7).

Secondary Outcome Measures :
  1. Clinician Administered PTSD Scale (CAPS) [ Time Frame: 6 Weeks ]

    The CAPS was developed at the National Center for PTSD and has become the "gold standard" for assessing Post Traumatic Stress Disorder. It is a user-friendly structured interview for screening, differential diagnosis, comfirming PTSD diagnosis or identifying Acute Stress Disorder.

    The CAPS will be assessed at the screening visit and again at week 5 (vist 7). Change scores (from screening to week 5) will be secondary efficacy measures.

  2. Insomnia Severity Index (ISI) [ Time Frame: 5 Weeks ]

    The ISI is a 7-item patient rated questionnaire that evaluates severity of sleep onset and maintenance difficulties, satisfaction with current sleep pattern interference with daily functioning, appearance of impairment attributed to the sleep problem, and the degree of concern caused by insomnia.

    Secondary outcome measures using the ISI will be determined using change scores from baseline to week 5 (visit 7)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Post Traumatic Stress Disorder according to DSM-IV
  • Must be able to speak, read and understand the English language and be able to provide written informed consent

Exclusion Criteria:

  • current, unstable and significant medical condition/illness
  • bronchial asthma or related bronchospastic condition
  • AV block
  • Sick Sinus Syndrome
  • Bradycardia
  • Peripheral hear disease
  • Unstable thyroid disorder
  • History of seizure disorder
  • Females who are pregnant, lactating or planning to become pregnant
  • Bipolar
  • Schizophrenia
  • Dementia
  • Intolerance or hypersensitivity to alpha or beta blockers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01221792

United States, California
Artemis Institute for Clinical Research
San Diego, California, United States, 92123
United States, Louisiana
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States, 70601
United States, Washington
Northwest Clinical Research Center
Bellevue, Washington, United States, 98007
Sponsors and Collaborators
Columbia Northwest Pharmaceuticals
Study Director: Arifulla Khan, MD Columbia Northwest Pharmaceuticals, LLC

Additional Information:
Responsible Party: Arifulla Khan, MD, Columbia Northwest Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01221792     History of Changes
Other Study ID Numbers: CVD-PT-10203
First Posted: October 15, 2010    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: June 2011

Keywords provided by Columbia Northwest Pharmaceuticals:
Post Traumatic Stress Disorder
Combat veteran
Sleep Disturbance

Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Pathologic Processes
Trauma and Stressor Related Disorders
Mental Disorders
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists